Learn about BYDUREON® BCiseTM including efficacy, safety, PK profile, and dosing, and available resources, including Important Safety Information. Find dosing and administration information for BYDUREON Pen, including BYDUREON Pen packaging contains 4 pens .. BYDUREON [package insert]. PACKAGE LEAFLET: INFORMATION FOR THE USER. Bydureon 2 mg powder and solvent for prolonged-release suspension for injection in pre-filled pen.

Author: Kajikasa Kajigor
Country: Benin
Language: English (Spanish)
Genre: Health and Food
Published (Last): 9 April 2009
Pages: 78
PDF File Size: 3.59 Mb
ePub File Size: 14.83 Mb
ISBN: 831-8-84276-540-1
Downloads: 74455
Price: Free* [*Free Regsitration Required]
Uploader: Terisar

Encapsulation of exenatide in poly- D,L-lactideco-glycolide microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes. You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents.

Bydureon package insert Patients may develop antibodies to exenatide. I have read this warning and will not be using any of the byddureon product information for clinical purposes. bydureon package insert

FDA Internet Application Site (Accessdata) Error

Efficacy bydureon package insert safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes DURATION Not studied in patients with a history of pancreatitis. Some of these injection-site reactions have required surgery.

We encourage you to read the privacy policy of every website you visit. GLP-1 RA, glucagon-like peptide-1 receptor agonist. After initiation, observe patients carefully for symptoms of bydurfon. Injection-Site Reactions Serious reactions eg, abscess, cellulitis, and necrosiswith or without bydureon package insert nodules, have been reported.

Gastrointestinal Disease Because exenatide is commonly associated with gastrointestinal adverse reactions, not recommended in patients with severe gastrointestinal disease eg, gastroparesis. bydureon package insert

BYDUREON Dosing and Administration

Find out more about how we use cookies and how to manage them by reading our cookie notice. For more information, call the Customer Packaye Center at Encapsulation of exenatide in poly- D,L-lactide-co-glycolide microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes.

  BIOGRAFII CELEBRE EPUB

Hypoglycemia Risk of hypoglycemia is increased byfureon exenatide is coadministered with insulin or insulin secretagogues. How can we help you today? Not recommended as first-line therapy for patients inadequately controlled on diet and exercise. Exenatide once weekly improved hour glucose control and reduced glycaemic variability in metformin-treated participants with type 2 diabetes: Exenatide extended-release causes bydureon package insert increased incidence in thyroid C-cell tumors at clinically relevant exposures in rats compared to controls.

If worsening of or failure to achieve adequate glycemic control occurs, consider alternative antidiabetic therapy Hypersensitivity Reports of serious hypersensitivity reactions eg, anaphylaxis and angioedema.

Please refer byduteon your approved national product label SmPC for current product information. I disagree I agree. If worsening of or failure to achieve adequate glycemic control occurs, consider alternative antidiabetic therapy Hypersensitivity Reports of serious hypersensitivity reactions bydureon package insert, anaphylaxis and angioedema. Patients with higher titer antibodies may have an attenuated HbA1c response. Hypersensitivity Reports of serious hypersensitivity reactions eg, anaphylaxis and bydureon package insert.

The most common side effects with BYDUREON may include nausea, diarrhea, headache, vomiting, constipation, itching at the injection site, a small bump nodule at the injection site, and indigestion. In people who have bydureon package insert problems, diarrhea, nausea, and vomiting may cause a loss of fluids dehydration which may cause kidney problems to get worse.

Important notice for users You are about to access AstraZeneca historic bydureon package insert material. Exenatide extended-release causes an increased incidence in thyroid C-cell tumors at clinically relevant exposures in rats compared to controls.

Use caution in patients with renal transplantation or moderate renal impairment. Injection-Site Reactions Serious reactions eg, abscess, cellulitis, and necrosiswith or without subcutaneous nodules, have been reported.

Product Information

Signs and symptoms of low blood sugar include dizziness or lightheadedness, sweating, confusion or drowsiness, headache, blurred vision, slurred speech, shakiness, fast bydureon package insert, anxiety, bydureon package insert, mood changes, hunger, weakness, or feeling jittery. Help me understand type 2 diabetes better. Macrovascular Outcomes No clinical studies establishing conclusive evidence of macrovascular risk reduction with exenatide.

  COMPUTER ORGANISATION BY MORRIS MANO PDF

If suspected, discontinue promptly and do not restart if confirmed. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: If worsening of or failure to achieve adequate glycemic control occurs, consider alternative antidiabetic therapy.

Not recommended as first-line therapy for patients inadequately controlled on diet bydureon package insert exercise. Any reference in these archives to AstraZeneca products or their uses may not reflect current medical knowledge and should not bydureon package insert used as a source of information on the present product label, efficacy data or safety data. Accessed October 18, Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: Use caution in patients with renal transplantation or moderate renal impairment Gastrointestinal Disease Because exenatide is commonly associated with gastrointestinal adverse reactions, not recommended in patients with severe gastrointestinal disease eg, gastroparesis Immunogenicity Patients may develop antibodies to exenatide.

Macrovascular Outcomes No clinical bydureon package insert establishing conclusive evidence of macrovascular risk reduction with exenatide. For adults with type 2 diabetes mellitus uncontrolled on one or more oral antidiabetic agents in addition to diet and exercise. Talk to your healthcare provider about managing low blood sugar.

Search Search Search Close. J Clin Endocrinol Metab.